meta|Evidence - COVID-19
anticoagulant, curative dose 2
anticoagulant, prophylactic dose 4
anti-inflammatoty and immuno-therapy
non-steroidal anti-inflammatory drugs 5
convalescent plasma treatment 18
inactivated mycobacterium vaccine
SNG001 inhaled interferon beta 1
anakinra 2
sarilumab azithromycin hydroxychloroquine
tocilizumab 19
Polyinosinic-Polycytidylic Acid
antiviral and associated therapy
azvudine 1
darunavir/cobicistat plus chloroquine
favipiravir 15
hydroxychloroquine plus macrolides 9
ivermectin 23
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b 1
Renin-angiotensin-system-acting agents 8
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
continuous positive airway pressure (CPAP)
nitric oxide (gas Inhalation or releasing solution)
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
![]() |
![]() |
![]() |
-
About
-
Our approach
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-